Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: When shock treatment goes wrong

Michael Griffiths, regional director of healthcare at specialist insurance brokers Howden, explains how shock treatment gone wrong established a legal benchmark for Singapore.

In 1957, a patient walked into a London clinic seeking treatment for a mental illness. The doctors recommended electro-convulsive therapy, otherwise known as shock treatment, to which the patient agreed. There was no discussion of the potential risks of the therapy, and neither muscle relaxants nor restraints were used. When the electric charge was applied, the patient thrashed around so violently that he suffered a broken hip and other serious injuries. Despite this, no finding of negligence was made against the clinic or the doctors. The court held that as there was a significant proportion of doctors who did not advocate the use of relaxants or restraints, and that it was normal medical practice at the time for no details of treatment risks to be disclosed, there had been no professional negligence. 

The patient’s name was Mr Bolam, and the Bolam test has long been the standard employed by Singapore’s courts in determining cases of alleged medical negligence. Essentially, a doctor could not be found negligent provided that his actions were supported by the opinions and practices of a substantial body of other reputable doctors. The fact that this test takes no account of the patient’s own perspective is perhaps a reflection of the doctor-patient dynamic prevailing in 1950’s England. 

As any doctor will confirm, however, patient expectations have changed dramatically in recent years and the Bolam test has been subject to criticism for its’ failure to consider the patient.

In 2015, the English Supreme Court handed down a decision in Montgomery vs Lanarkshire Health Board that effectively removed the Bolam test for determining whether informed consent had been obtained. Now, Singapore’s Court of Appeal has followed suit.

In 2010 Hii Chii Kok sought treatment at Singapore’s National Cancer Centre. Scans had revealed pancreatic lesions that were potentially malignant, although this could not be determined conclusively by the scans alone. Hii decided to proceed with surgery and the lesions were successfully removed. Upon examination the lesions proved not to be cancerous, and to make matters worse Hii suffered post-operative complications that required two further operations. He took legal action against the surgeon and the National Cancer Centre, where his lawyers argued that the treating doctor should have advised the patient to follow an alternative treatment option, and that the defence offered by the Bolam test should not be available. 

While the Court of Appeal ultimately rejected Hii’s suit, they did impose a new test that replaces the Bolam test in relation to advice and consent, and that recognises a far more active patient participation in decision-making. Doctors in Singapore must now ensure that patients are provided with all relevant information and materials to enable them to make informed decisions regarding their own treatment, and any decision by a doctor to withhold such information or materials will need to be justified.

So what does all this mean for medical malpractice litigation in Singapore? 

Well, we have not seen a flood of new cases as a result of this ruling. However, the more onerous requirements that Singapore’s doctors must now meet in relation to patient advice will surely give rise to a greater number of claims concerning advice and consent. We have been reporting for some time on the increasing incidence of medical malpractice claims in Singapore, and the removal of the Bolam test will do nothing to reverse this trend.

Posted on: 02/11/2017 UTC+08:00


Medical diagnostic imaging services provider Capitol Health has said that it expects to return to profitability in the next financial year and has upgraded its outlook for the year.
Paragon Care, a leading distributor and manufacturer supplying medical equipment to hospitals, has said that it is “targeting strong growth in 2018 across all key metrics”.
Malaysian medical glove manufacturer Supermax Group has reported a 42.8% jump in Q1 profits to M$27.9 million (US$6.8 million) on revenues that 16% to M$312 million.
At its annual general meeting, international pathology, imaging and medical centres operator Sonic Healthcare reaffirmed guidance for the year. Chief executive Colin Goldschmidt said that the first quarter of the 2019 financial year confirmed expectations that underlying earnings would grow between 6% and 8% on a constant currency basis.
It has been another great quarter for China Cord Blood Corporation (CCBC), the country’s largest provider of cord blood storage and ancillary services. For the second quarter in a row, profits more than doubled. They came in at US$10.2 million.
New Zealand-based medical device manufacturer Fisher & Paykel Healthcare has reported a steady set of first half figures. Profits were up 4% to NZ$81.3 million (US$55.3 million) on revenues that rose 8% to NZ$458.4 million.
Retirement village operator Arvida has reported a 14.5% slump in profits for the first half of the year to NZ$14.5 million (US$9.9 million). At the same time, revenues were up 27.9% to NZ$60 million.
Medical device manufacturer Microport Scientific Corporation plans to acquire the cardiac rhythm management (CRM) business of London-based medical device manufacturer LivaNova for US$190 million.


The promise of a bottom in Singapore’s office market has caused its ranking as an investment market to soar from next-to-bottom last year to third in this year’s “Emerging Trends in Real Estate Asia Pacific 2018” report, a real estate forecast jointly published by the Urban Land Institute (ULI) and PwC.
Kamal Brar, vice president and general manager of Asia Pacific for data software company Hortonworks, looks at how data analytics can provide effective and affordable healthcare in Singapore.
The latest Sun Life Financial Asia Diabetes Awareness Study reveals an alarming knowledge gap in diabetes. A third of Asian women who are or were pregnant in the past three years are unaware of the risk of developing gestational diabetes in pregnancy, while one in seven births in Asia is currently affected by gestational diabetes.
Gan Kim Yong, Singapore’s minister for health, explains why the private sector needs to get behind the National Electronic Health Record System.
Business leaders in Asia Pacific’s healthcare industry are showing urgency in embracing the fourth industrial revolution, according to the Microsoft Asia Digital Transformation Survey. More than three-quarters of them believe that they need to transform to a digital business to enable future growth and yet only a quarter said that they have a full digital strategy in place today.
An agreement for an additional US$15 million funding from the World Bank will be used to expand health and nutrition coverage in the Lao People's Democratic Republic. It is expected to benefit more than 1 million people across 14 provinces.
Bart Van den Mooter, CEO of the TforG Group, looks at the drivers behind the rapid growth in Asia’s medical tourism market.
The ambitious healthcare agenda under Moon Jae-in's liberal presidency will seek to expand national health insurance reimbursement and limit the burden of excessive medical costs, while overhauling the healthcare system. BMI Research looks at the winners and the losers in the presidential agenda.




Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices